Egypt Hepatitis C treatment drug market is anticipated to register a lucrative growth over the forecast period, 2023-2027. Hepatitis C is an infection caused by a virus that mainly attacks the liver and leads to inflammation. This infection is spread by the contact with contaminated blood or other bodily fluids. Hepatitis can be acute or chronic, but type C of Hepatitis is one of the most hazardous and hard to treat. The market growth can be attributed to the growing prevalence of hospital-acquired infections (HAIs) that a patient generally gets while receiving treatment from a clinic or hospital from a healthcare professional. This has resulted in the development of Hepatitis C treatment drugs and new product launches, such as the launch of fixed-dose combinations. Moreover, the rising coordinated efforts for the research and development of powerful medications to treat Hepatitis C is creating a positive impact on the market. Moreover, the leading market players are continuously focusing on utilizing innovative technologies for the development of medications to enhance the effectiveness and efficiency of the medicines for the treatment of Hepatitis C patients.
Introduction of Advanced Treatment Drugs to Fuel the Market Growth
Government Initiatives to Accelerate the Market Growth
The adoption of new treatment drugs is increasing at a fast pace due to the several initiatives taken by the government to educate the patients regarding the new therapeutics. This is providing a positive outlook to the Egypt market. In addition, the governments of several countries are allocating funds to the concerned authorities to provide hepatitis C treatment drugs at a subsidized rate, which is also strengthening the market growth. Furthermore, the increasing number of clinical trials and successful drug clearances have supplemented the overall growth of the hepatitis C market. For instance, since 2014, Egypt has increased the healthcare services to eliminate HCV, which is followed by the President Abdel Fatah al-Sisi's initiative to treat 1 million HCV-infected patients annually and reduce the risk of mortality and morbidity. Such programs are anticipated to provide lucrative growth opportunities to the Egypt hepatitis C treatment drugs market.
DOWNLOAD FREE SAMPLE REPORT
Market Segmentation
The Egypt Hepatitis C treatment drug market is segmented by disease type, drug class, distribution channel, competitive landscape, and regional distribution.
Company Profile
GlaxoSmithKline, Plc., Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG are the leading market players of the Egypt Hepatitis C treatment drug market.
| Attribute | Details |
| Base Year | 2021 |
| Historical Data | 2017 – 2020 |
| Estimated Year | 2022 |
| Forecast Period | 2023 – 2027 |
| Quantitative Units | Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | · Disease Type · Drug Class · Distribution Channel |
| Regional Scope | Cairo, Alexandria, Giza, Qalyubia, Port Said, Suez, and Rest of Egypt. |
| Key companies profiled | GlaxoSmithKline, Plc., Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, and F. Hoffmann-La Roche AG |
| Customization scope | 10% free report customization with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
